Fast Track Speeds Approval, Tufts Finds; Therapeutic Category Also Key
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s fast track program may be the most successful of FDA’s user fee-era regulatory initiatives aimed at speeding new drug reviews, an analysis by the Tufts Center for the Study of Drug Development suggests.
You may also be interested in...
Oncology Review Division At The Head Of The Pack – But Can The Others Keep Up?
Analysis of drug review performance by division finds Cardiovascular & Renal Drugs Division to occupy the lower end of the spectrum. Staffing appears to be a vital component of review performance, giving weight to the researchers’ warning of impending wholesale staff turnover.
Big Pharma Keeps CNS Pipeline In-House; GI/Metabolism Left To Specialists
For the analysis, published in the September/October 2010 Tufts CSDD Impact Report, researchers tracked clinical activity at the 50 largest pharmaceutical and biopharmaceutical companies ranked by total 2006 worldwide sales. The study analyzed factors related to clinical approval success for compounds entering the clinic between 1993 and 2004.
Lessons Learned: New FDA Guidance On Meetings With Sponsors Adds Depth
FDA's new iteration of its guidance on meetings with sponsors reflects lessons learned during the surge in meeting requests the agency has had in the nine years since the original formal meetings final guidance was issued in February 2000